(Q49957645)

23 February 2018

title

Imaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions. (English)

1 reference

23 February 2018

0 references

4

Colin L Masters

1 reference

23 February 2018

Victor L Villemagne

1

1 reference

23 February 2018

Vincent Doré

series ordinal

2

1 reference

23 February 2018

Samantha C Burnham

series ordinal

3

1 reference

23 February 2018

Christopher C Rowe

series ordinal

5

1 reference

23 February 2018

language of work or name

English

0 references

publication date

16 February 2018

1 reference

23 February 2018

published in

Nature Reviews Neurology

1 reference

23 February 2018

https://scigraph.springernature.com/pub.10.1038/nrneurol.2018.9

exact match

0 references

cites work

The A4 study: stopping AD before symptoms begin?

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Testing the right target and right drug at the right stage

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Diagnosis of Alzheimer's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Alzheimer's disease and Down's syndrome: roles of APP, trophic factors and ACh.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Mild cognitive impairment: clinical characterization and outcome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Mild cognitive impairment--beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Revising the definition of Alzheimer's disease: a new lexicon.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Amyloid, the presenilins and Alzheimer's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Amyloid PET Ligands for Dementia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Florbetapir f-18: a histopathologically validated Beta-amyloid positron emission tomography imaging agent.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Amyloid deposition detected with florbetapir F 18 ((18)F-AV-45) is related to lower episodic memory performance in clinically normal older individuals

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Florbetapir F 18 amyloid PET and 36-month cognitive decline: a prospective multicenter study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Use of Florbetapir-PET for Imaging β-Amyloid Pathology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

F-18 stilbenes as PET imaging agents for detecting beta-amyloid plaques in the brain

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

In vitro characterization of [18F]-florbetaben, an Aβ imaging radiotracer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: phase 3 study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

18F-florbetaben Aβ imaging in mild cognitive impairment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Aβ imaging with 18F-florbetaben in prodromal Alzheimer's disease: a prospective outcome study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Synthesis of 18F-labelled 2-(4'-fluorophenyl)-1,3-benzothiazole and evaluation as amyloid imaging agent in comparison with [11C]PIB.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Combination of biomarkers: PET [18F]flutemetamol imaging and structural MRI in dementia and mild cognitive impairment.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Association between in vivo fluorine 18-labeled flutemetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Delineation of positron emission tomography imaging agent binding sites on beta-amyloid peptide fibrils.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Frequency of stages of Alzheimer-related lesions in different age categories

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

11C-PiB PET studies in typical sporadic Creutzfeldt-Jakob disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Positron emission tomography and neuropathologic estimates of fibrillar amyloid-β in a patient with Down syndrome and Alzheimer disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

An in vivo evaluation of cerebral cortical amyloid with [18F]flutemetamol using positron emission tomography compared with parietal biopsy samples in living normal pressure hydrocephalus patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Quantitative neurohistological features of frontotemporal degeneration.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Amyloid tracers detect multiple binding sites in Alzheimer's disease brain tissue.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

High striatal amyloid beta-peptide deposition across different autosomal Alzheimer disease mutation types

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

PET amyloid ligand [11C]PIB uptake shows predominantly striatal increase in variant Alzheimer's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Evaluating atypical dementia syndromes using positron emission tomography with carbon 11 labeled Pittsburgh Compound B.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

In vivo demonstration of amyloid burden in posterior cortical atrophy: a case series with PET and CSF findings

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Spatial relation between microbleeds and amyloid deposits in amyloid angiopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Imaging of amyloid burden and distribution in cerebral amyloid angiopathy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Imaging beta-amyloid burden in aging and dementia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Measurement of longitudinal β-amyloid change with 18F-florbetapir PET and standardized uptake value ratios

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Brain β-amyloid load approaches a plateau

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Amyloid-beta plaque growth in cognitively normal adults: longitudinal [11C]Pittsburgh compound B data

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Standardized Expression of 18F-NAV4694 and 11C-PiB β-Amyloid PET Results with the Centiloid Scale

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

(18)F-Florbetaben PET beta-amyloid binding expressed in Centiloids

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Amyloid imaging in dementias with atypical presentation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Imaging amyloid deposition in Lewy body diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

[(11)C]-PIB imaging in patients with Parkinson's disease: preliminary results.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Striatal Aβ peptide deposition mirrors dementia and differentiates DLB and PDD from other parkinsonian syndromes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Frontotemporal lobar degeneration: epidemiology, pathophysiology, diagnosis and management

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

In vivo amyloid imaging with PET in frontotemporal dementia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Abeta amyloid and glucose metabolism in three variants of primary progressive aphasia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Subtypes of progressive aphasia: application of the International Consensus Criteria and validation using β-amyloid imaging.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Atypical frontotemporal lobar degeneration with ubiquitin-positive, TDP-43-negative neuronal inclusions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Frontotemporal lobar degeneration and ubiquitin immunohistochemistry

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

[11C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

A4 amyloid protein deposition and the diagnosis of Alzheimer's disease: prevalence in aged brains determined by immunocytochemistry compared with conventional neuropathologic techniques.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Cortical biochemistry in MCI and Alzheimer disease: lack of correlation with clinical diagnosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Comparison of 18F-FDG and PiB PET in cognitive impairment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

In vivo human amyloid imaging

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Increased metabolic vulnerability in early-onset Alzheimer's disease is not related to amyloid burden

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Longitudinal stability of CSF biomarkers in Alzheimer's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Toward a multifactorial model of Alzheimer disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Amyloid load and cerebral atrophy in Alzheimer's disease: an 11C-PIB positron emission tomography study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Amyloid-β associated cortical thinning in clinically normal elderly

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Beta-amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Spatial patterns of brain amyloid-beta burden and atrophy rate associations in mild cognitive impairment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Neuronal dysfunction and disconnection of cortical hubs in non-demented subjects with elevated amyloid burden

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Regional expansion of hypometabolism in Alzheimer's disease follows amyloid deposition with temporal delay

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Accelerated cortical atrophy in cognitively normal elderly with high β-amyloid deposition.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Cross-sectional and longitudinal analysis of the relationship between Aβ deposition, cortical thickness, and memory in cognitively unimpaired individuals and in Alzheimer disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Atrophy rates in asymptomatic amyloidosis: implications for Alzheimer prevention trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Acceleration of hippocampal atrophy rates in asymptomatic amyloidosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

PET amyloid ligand [11C]PIB uptake and cerebrospinal fluid beta-amyloid in mild cognitive impairment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

PET imaging of amyloid deposition in patients with mild cognitive impairment.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Longitudinal change in CSF Tau and Aβ biomarkers for up to 48 months in ADNI

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Nonlinear Association Between Cerebrospinal Fluid and Florbetapir F-18 β-Amyloid Measures Across the Spectrum of Alzheimer Disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β-amyloid

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

High PIB retention in Alzheimer's disease is an early event with complex relationship with CSF biomarkers and functional parameters

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Relationship of cerebrospinal fluid markers to 11C-PiB and 18F-FDDNP binding

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Frequent amyloid deposition without significant cognitive impairment among the elderly

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Cognition, glucose metabolism and amyloid burden in Alzheimer's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Basal cerebral metabolism may modulate the cognitive effects of Abeta in mild cognitive impairment: an example of brain reserve.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Pro: Can biomarkers be gold standards in Alzheimer's disease?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Synergistic effect of β-amyloid and neurodegeneration on cognitive decline in clinically normal individuals.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Preclinical AD predicts decline in memory and executive functions in subjective complaints

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Tau positron emission tomographic imaging in aging and early Alzheimer disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

The behavioural/dysexecutive variant of Alzheimer's disease: clinical, neuroimaging and pathological features

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

PET Imaging of Tau Deposition in the Aging Human Brain.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Tau imaging: early progress and future directions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Discovery of 6-(Fluoro-(18)F)-3-(1H-pyrrolo[2,3-c]pyridin-1-yl)isoquinolin-5-amine ([(18)F]-MK-6240): A Positron Emission Tomography (PET) Imaging Agent for Quantification of Neurofibrillary Tangles (NFTs).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Breast cancer detection using high-resolution breast PET compared to whole-body PET or PET/CT.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Identification of Three Novel Radiotracers for Imaging Aggregated Tau in Alzheimer's Disease with Positron Emission Tomography.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Preclinical Evaluation of 18F-JNJ64349311, a Novel PET Tracer for Tau Imaging

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

High affinity radiopharmaceuticals based upon lansoprazole for PET imaging of aggregated tau in Alzheimer's disease and progressive supranuclear palsy: synthesis, preclinical evaluation, and lead selection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Tau aggregation in the hippocampal formation: an ageing or a pathological process?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Association of In Vivo [18F]AV-1451 Tau PET Imaging Results With Cortical Atrophy and Symptoms in Typical and Atypical Alzheimer Disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Is Tau Imaging More Than Just Upside-Down 18F-FDG Imaging?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Longitudinal changes of tau PET imaging in relation to hypometabolism in prodromal and Alzheimer's disease dementia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Location, location, location!

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Dynamic PET Measures of Tau Accumulation in Cognitively Normal Older Adults and Alzheimer's Disease Patients Measured Using [18F] THK-5351

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Distinct tau PET imaging patterns in typical and atypical Alzheimer's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between β-Amyloid and Tauopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Tau PET in Alzheimer disease and mild cognitive impairment.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Atrophy patterns in early clinical stages across distinct phenotypes of Alzheimer's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Tau, amyloid, and hypometabolism in a patient with posterior cortical atrophy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

The relationship between cerebrospinal fluid markers of Alzheimer pathology and positron emission tomography tau imaging

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Observations on the brains of demented old people

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

PART, a distinct tauopathy, different from classical sporadic Alzheimer disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

PART is part of Alzheimer disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Tau aggregation influences cognition and hippocampal atrophy in the absence of beta-amyloid: a clinico-imaging-pathological study of primary age-related tauopathy (PART).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Biomarker modeling of Alzheimer's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

In vivo evaluation of a novel tau imaging tracer for Alzheimer's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

AV-1451 tau and β-amyloid positron emission tomography imaging in dementia with Lewy bodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Tau imaging with [18 F]THK-5351 in progressive supranuclear palsy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Tau imaging in progressive supranuclear palsy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

The neuropathology of frontotemporal lobar degeneration with respect to the cytological and biochemical characteristics of tau protein

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

A new subtype of frontotemporal lobar degeneration with FUS pathology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Neuropathologic, biochemical, and molecular characterization of the frontotemporal dementias

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

[F-18]AV-1451 positron emission tomography retention in choroid plexus: More than "off-target" binding

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Pathological correlations of [F-18]-AV-1451 imaging in non-alzheimer tauopathies.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Effects of transthyretin on thyroxine and β-amyloid removal from cerebrospinal fluid in mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Biondi ring tangles in the choroid plexus of Alzheimer's disease and normal aging brains: a quantitative study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

An autoradiographic evaluation of AV-1451 Tau PET in dementia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

[F-18]-AV-1451 binding correlates with postmortem neurofibrillary tangle Braak staging.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

18 F-flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: A multicenter study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

The ART of loss: Abeta imaging in the evaluation of Alzheimer's disease and other dementias

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Biomarkers for early detection of Alzheimer pathology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Amyloid imaging in prodromal Alzheimer's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Amyloid-dependent and amyloid-independent stages of Alzheimer disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Accuracy of early diagnosis and its impact on the management and course of Alzheimer's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Predicting Alzheimer disease with β-amyloid imaging: results from the Australian imaging, biomarkers, and lifestyle study of ageing.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Challenges in the conduct of disease-modifying trials in AD: practical experience from a phase 2 trial of Tau-aggregation inhibitor therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

Recommendations for the incorporation of biomarkers into Alzheimer clinical trials: an overview.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

How golden is the gold standard of neuropathology in dementia?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

α-synuclein imaging: a critical need for Parkinson's disease research.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2018.9

7 January 2021

inferred from DOI database lookup

Biochemical and anatomical redistribution of tau protein in Alzheimer's disease

1 reference

12 December 2020

Mild cognitive impairment: transition between aging and Alzheimer's disease.

1 reference

12 December 2020

Magnetic resonance imaging white matter hyperintensities and brain volume in the prediction of mild cognitive impairment and dementia.

1 reference

12 December 2020

Relationship between atrophy and beta-amyloid deposition in Alzheimer disease

1 reference

12 December 2020

In vivo fibrillar beta-amyloid detected using [11C]PiB positron emission tomography and neuropathologic assessment in older adults

1 reference

12 December 2020

Longitudinal patterns of β-amyloid deposition in nondemented older adults

1 reference

12 December 2020

Biomarkers of Alzheimer disease: current and future applications to diagnostic criteria

1 reference

12 December 2020

Critical review of the Appropriate Use Criteria for amyloid imaging: Effect on diagnosis and patient care

1 reference

12 December 2020

Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRNEUROL.2018.9

1 reference

23 February 2018

Dimensions Publication ID

0 references

1 reference

23 February 2018